84 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
payments made to such holder, unless such holder enters into an agreement with the U.S. Department of Treasury to collect and provide substantial
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
Stockholders’ Equity Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying us that we
8-K
ATXI
Avenue Therapeutics Inc
15 Mar 24
Other Events
7:15am
the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it was not in compliance
424B3
imnhfxlrx5k118kn1ki
2 Feb 24
Prospectus supplement
12:00am
8-K
2jhgp
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1:19pm
8-K
EX-99.1
o12ed7 e6qlznrmkahxn
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-99.2
4yap zlu6y532m9ye
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.2
sb7xr9xzuk
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
722gq8w6j6q8b
2 Nov 23
Prospectus supplement with pricing info
9:00am
8-K
nrtgxo5tw2idc 0wr
28 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:25pm
8-K
9wj1rkm7zex19
21 Jul 23
Other Events
4:37pm